These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

54 related articles for article (PubMed ID: 22846869)

  • 21. Limited value of CA 19-9 in predicting early treatment failure in patients with advanced pancreatic cancer.
    Vormittag L; Gleiss A; Scheithauer W; Lang F; Laengle F; Kornek GV
    Oncology; 2009; 77(2):140-6. PubMed ID: 19628952
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictors of malignant intraductal papillary mucinous neoplasm of the pancreas.
    Mimura T; Masuda A; Matsumoto I; Shiomi H; Yoshida S; Sugimoto M; Sanuki T; Yoshida M; Fujita T; Kutsumi H; Ku Y; Azuma T
    J Clin Gastroenterol; 2010 Oct; 44(9):e224-9. PubMed ID: 20453661
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Small pancreatic cancer diagnosis and prognosis].
    Zhang JW; Sun YM; Bian ZM; Shi SS; Wang CF; Zhao P
    Zhonghua Zhong Liu Za Zhi; 2009 May; 31(5):375-9. PubMed ID: 19799088
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Current diagnosis and treatment of early pancreatic cancer].
    Ryu S; Maeshiro K; Yasunami Y; Ikeda S
    Nihon Rinsho; 1996 May; 54(5):1390-4. PubMed ID: 8965372
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term survival following resection of brain metastases from pancreatic cancer.
    Lemke J; Barth TF; Juchems M; Kapapa T; Henne-Bruns D; Kornmann M
    Anticancer Res; 2011 Dec; 31(12):4599-603. PubMed ID: 22199336
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
    Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P
    Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Undetectable preoperative levels of serum CA 19-9 correlate with improved survival for patients with resectable pancreatic adenocarcinoma.
    Berger AC; Meszoely IM; Ross EA; Watson JC; Hoffman JP
    Ann Surg Oncol; 2004 Jul; 11(7):644-9. PubMed ID: 15197014
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Management of sporadic pancreatic desmoid tumors.
    Hina M; Lynch BA; Herdman AV; Stanley JD
    Am Surg; 2012 Jan; 78(1):E1-3. PubMed ID: 22273281
    [No Abstract]   [Full Text] [Related]  

  • 29. Prognostic impact of postoperative serum CA 19-9 levels in patients with resectable pancreatic cancer.
    Hata S; Sakamoto Y; Yamamoto Y; Nara S; Esaki M; Shimada K; Kosuge T
    Ann Surg Oncol; 2012 Feb; 19(2):636-41. PubMed ID: 21863360
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinicopathological features in misdiagnosed pancreatic carcinoma.
    Nagahama H; Okada S; Okusaka T; Ishii H; Ikeda M; Nakasuka H; Yoshimori M
    Hepatogastroenterology; 1999; 46(29):2983-5. PubMed ID: 10576387
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The definition of locally advanced pancreatic cancer.
    Zanini N; Masetti M; Jovine E
    Br J Cancer; 2010 Apr; 102(8):1306-7; author reply 1308. PubMed ID: 20354530
    [No Abstract]   [Full Text] [Related]  

  • 32. Surgical treatment for patients with advanced pancreatic cancer.
    Ihse I; Andersson R; Axelson J; Hansson L
    J Hepatobiliary Pancreat Surg; 1998; 5(2):133-7. PubMed ID: 9745078
    [No Abstract]   [Full Text] [Related]  

  • 33. Could standard ISO 15189 be useful for the conundrum of CA 19-9/GI Monitor measurement?
    Dorizzi RM; Meneghelli S; Rocca M; Ferrari A
    Clin Chem Lab Med; 2007; 45(7):928-9. PubMed ID: 17617041
    [No Abstract]   [Full Text] [Related]  

  • 34. Invisible pancreatic cancer: the cuff sign.
    Nagahata K; Kawakami Y; Nakase H
    QJM; 2024 Jul; 117(7):525-526. PubMed ID: 38450418
    [No Abstract]   [Full Text] [Related]  

  • 35. Recent advances in the surgical treatment of pancreatic cancer.
    Shankar A; Russell RC
    World J Gastroenterol; 2001 Oct; 7(5):622-6. PubMed ID: 11819842
    [No Abstract]   [Full Text] [Related]  

  • 36. Pancreatic cancer: a neglected killer?
    Lancet Oncology
    Lancet Oncol; 2010 Dec; 11(12):1107. PubMed ID: 21126681
    [No Abstract]   [Full Text] [Related]  

  • 37. Management of borderline and locally advanced pancreatic cancer: where do we stand?
    He J; Page AJ; Weiss M; Wolfgang CL; Herman JM; Pawlik TM
    World J Gastroenterol; 2014 Mar; 20(9):2255-66. PubMed ID: 24605025
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Locally advanced pancreatic cancer.
    Auriemma WS; Berger AC; Bar-Ad V; Boland PM; Cohen SJ; Roche-Lima CM; Morris GJ
    Semin Oncol; 2012 Aug; 39(4):e9-22. PubMed ID: 22846869
    [No Abstract]   [Full Text] [Related]  

  • 39. Evaluating the efficacy of tumor markers CA 19-9 and CEA to predict operability and survival in pancreatic malignancies.
    Mehta J; Prabhu R; Eshpuniyani P; Kantharia C; Supe A
    Trop Gastroenterol; 2010; 31(3):190-4. PubMed ID: 21560524
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Primary pancreatic lymphoma: a clinical quandary of diagnosis and treatment.
    Du X; Zhao Y; Zhang T; Liao Q; Dai M; Liu Z; Guo J; Hu Y
    Pancreas; 2011 Jan; 40(1):30-6. PubMed ID: 20683215
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.